Peptide · Recovery & Tissue Repair
BPC-157 / TB500
A two-peptide recovery stack that pairs BPC-157's localized repair focus with TB-500's systemic reach — so support isn't confined to one strained spot but extends across the soft tissue that moves with it.
Available by consultation
What it is
Recovery Stack
This is a paired protocol, not a single molecule. BPC-157 (Body Protection Compound) is the localized partner — a synthetic 15-amino-acid peptide patterned on a protective sequence from gastric juice, studied for concentrated repair support at a specific tendon, joint, or gut lining. TB-500, a synthetic fragment of the naturally occurring protein Thymosin Beta-4, is the systemic partner: rather than acting at one site, it is studied for regulating actin and cell migration throughout the body, which is the rationale for broadening the effect toward whole-body flexibility and soft-tissue recovery. Stacked, TB-500 is meant to extend BPC-157 from a focused repair course into a wider recovery framework. It is a compounded therapy, prescribed only when a licensed provider determines it is clinically appropriate for you.
The point of pairing these two is complementary modes of action: BPC-157 is studied for repair signaling at a specific site, while TB-500 is studied for the cytoskeletal machinery that lets tissue migrate, glide, and remodel body-wide. Neither touches the endocrine axis.
BPC-157: localized repair signaling
BPC-157 is studied for amplifying repair at a targeted area — interacting with angiogenic (VEGFR2, nitric-oxide) and growth-factor pathways that feed a healing tendon, ligament, or gut-lining wound bed. This is the site-specific anchor of the stack, the same localized focus BPC-157 carries on its own.
TB-500: systemic actin & cell migration
This is what TB-500 uniquely adds to the pairing. As a Thymosin Beta-4 fragment, it is studied for binding G-actin and regulating the cytoskeleton — the process that lets cells migrate to and organize within tissue. Because that machinery is present body-wide, its studied effect is systemic rather than confined to one site, which is why it is framed as extending recovery beyond the single spot BPC-157 concentrates on.
Why the pairing is the point
BPC-157 is oriented toward repair at a defined location; TB-500 is studied for the mobility, flexibility, and cell migration that may help surrounding soft tissue recover in concert. The intent of stacking is coverage — a focused repair site plus whole-body soft-tissue support — rather than the narrower localized course BPC-157 offers by itself.
Candidacy
A considered fit, not a funnel.
This pairing tends to suit people whose recovery goal is broader than one isolated spot — someone who wants BPC-157's targeted repair focus on a specific tendon or joint but also TB-500's systemic support for overall flexibility and soft-tissue recovery. If your concern is a single, well-localized issue, plain BPC-157 may be the more appropriate starting point; the added TB-500 is for when whole-body reach matters. It is used to support recovery and is not a substitute for orthopedic, surgical, or gastroenterology care. A provider reviews your history to decide whether the pairing fits your goals.
- Active adults wanting both a targeted repair site (BPC-157) and broader soft-tissue reach (TB-500)
- Those focused on overall flexibility and range of motion, not just one strained area
- People seeking a non-hormonal recovery stack rather than a single-site peptide
- Anyone with an active or recent cancer diagnosis — BPC-157's angiogenic signaling and TB-500's cell-migration signaling are each a theoretical concern
- People who are pregnant or breastfeeding
- Anyone with a known hypersensitivity to either peptide or the diluent
Expected Timeline
What to expect
Because two peptides are involved, protocols often run them on different rhythms — BPC-157 tends toward a steady daily cadence for its target site, while TB-500 is frequently dosed less often but front-loaded early, reflecting its systemic profile. Your provider sets the exact pairing.
- 01
Weeks 1-2
Loading & initiation
Your provider establishes both agents — commonly a daily BPC-157 course alongside a front-loaded TB-500 schedule (often larger, less frequent doses early). Tolerability of the pair is confirmed before continuing.
- 02
Weeks 3-6
Active recovery
The core window where BPC-157 works its targeted site while TB-500 supports systemic soft-tissue recovery and flexibility. Many protocols hold BPC-157 daily and shift TB-500 toward a maintenance frequency as you and your provider track how both the site and overall mobility respond.
- 03
Weeks 6-8+
Taper & reassess
Rather than continuing indefinitely, the stack is commonly wound down and reassessed. Your provider decides whether a maintenance approach, a pause, or a stop makes sense for each peptide independently.
Response varies from person to person, and this is a compounded, provider-directed stack. The dosing rhythms for BPC-157 and TB-500 differ and are set and adjusted by your prescriber — the cadence above is illustrative, not a promise of any particular result.
The Science
Why clinicians reach for it.
The evidence base for both peptides is largely preclinical and early-stage, and controlled human research on the combination specifically is limited. We describe the direction of research honestly — no invented trials, no promised outcomes.
Two distinct research lineages
BPC-157 traces to a protective sequence found in gastric juice, which is why its research centers on localized and gut repair. TB-500 derives from Thymosin Beta-4, an actin-regulating protein — a separate body of work focused on cell migration and systemic tissue recovery. This stack combines two lineages rather than doubling one.
Complementary, not redundant
The rationale for pairing is that the peptides are studied for different mechanisms — BPC-157's site-specific repair signaling versus TB-500's systemic cytoskeletal regulation — so the interest is in coverage across both localized and whole-body soft-tissue recovery, not two peptides doing the same job.
Not FDA-approved
Neither BPC-157 nor TB-500 is an FDA-approved drug, and the combination is available only through compounding when a licensed provider deems it appropriate. It should be viewed as an emerging, supportive therapy — not an established treatment for any condition.
Our Standard of Care
Real transformation, with a friendly team that stands by you every step.
- 01.Provider-Supervised
- Licensed providers review your health profile and guide every treatment decision. You only move forward when a plan is right for you.
- 02.Personalized Plans
- GLP-1 and peptide protocols are titrated to your biology and your goals. No one-size-fits-all, no guesswork.
- 03.We Stand By You
- From eligibility review to ongoing check-ins, our care team supports you throughout your transformation — discreet shipping and secure messaging included.
Clinical Safety
No therapy is right for everyone.
What to know
Reported effects for both peptides are generally mild and may include irritation, redness, or discomfort at the injection site, and occasional lightheadedness, fatigue, or nausea. Because human safety data is limited — and even more so for the combination — any new or persistent symptom should be reported to your provider promptly.
Contraindications
Not appropriate during pregnancy or breastfeeding, or for anyone with a known hypersensitivity to either peptide or the diluent. Because BPC-157's angiogenic signaling and TB-500's cell-migration signaling are each a theoretical concern in the presence of malignancy, the stack is generally avoided in anyone with an active or recent cancer. Share your full medical history — including any cancer history — so your provider can assess suitability.
MagsRX protocols are prepared by partner compounding pharmacies in the United States. Compounding pharmacies are regulated by both state boards and the FDA and have been part of American medicine since long before mass-manufactured drugs existed. The active ingredient is prepared per your protocol — supervised by your provider — and delivered direct to your door.
Frequently Asked
Questions worth asking before you begin.
BPC-157 alone concentrates on localized repair at a specific site. Adding TB-500 — a Thymosin Beta-4 fragment studied for systemic cell migration and flexibility — is meant to broaden the focus from that one spot toward whole-body soft-tissue recovery. The stack is chosen when the goal is coverage beyond a single injury, not just repair support at one location.
TB-500's studied mechanism is systemic: it binds G-actin and is researched for regulating the cytoskeleton that lets cells migrate and tissue remodel throughout the body. BPC-157 is more site-focused. So TB-500 is the reason this pairing is framed around overall flexibility and range of motion, rather than the narrower localized focus BPC-157 carries on its own.
Usually not. BPC-157 is often run daily to support its target site, while TB-500 is commonly front-loaded early and then moved to a less frequent maintenance rhythm, reflecting its systemic profile. Your provider sets and adjusts each one independently based on how you respond.
Explore More
Other therapies to consider.
Tissue RepairBPC-157
A body-protection pentadecapeptide studied for how it may support the slow-healing places — a strained tendon, an irritable gut lining, a joint that lingers.
Learn more →- Tissue Repair
BPC-157 Acetate
The same BPC-157 pentadecapeptide, prepared as the acetate salt — the biocompatible counter-ion chosen for a clean compounded preparation that avoids residual TFA.
Learn more → - Complete Repair Stack
BPC-157 / GHK-Cu / KPV / TB500
Our broadest repair stack — four peptides that pair BPC-157/TB-500 tissue and soft-tissue support with GHK-Cu copper-led skin remodeling and KPV's anti-inflammatory lane.
Learn more →
Begin
BPC-157 / TB500 begins with a short assessment.
A licensed provider reviews every order and prescribes only if it is clinically appropriate for you. Your therapy is prepared by a partner compounding pharmacy and delivered discreetly to your door.